Example: Heart Attack

Search clinical trials for: Girls Can...Move!

Total 6084 results

NCT06528769

Recruiting

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Sarcoma | Leiomyosarcoma
NCT05733000

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Urothelial Carcinoma
NCT04175431

Recruiting

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Prostate Adenocarcinoma
NCT03504644

Active, not recruiting

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | Refractory T Acute Lymphoblastic Leukemia | Refractory T Lymphoblastic Lymphoma | Recurrent T Acute Lymphoblastic Leukemia | Recurrent T Lymphoblastic Lymphoma
NCT03213678

Completed

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm
NCT04581382

Completed

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Melanoma
NCT04941287

Active, not recruiting

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Recurrent Gallbladder Carcinoma | Metastatic Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Cholangiocarcinoma | Metastatic Distal Bile Duct Adenocarcinoma | Recurrent Distal Bile Duct Adenocarcinoma | Unresectable Liver Carcinoma
NCT07078604

Recruiting

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma
NCT07017829

Recruiting

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma
NCT06495125

Recruiting

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Adenocarcinoma | Refractory Lung Adenocarcinoma
NCT06453044

Recruiting

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular Lymphoma | Refractory Grade 2 Follicular Lymphoma | Refractory Grade 3a Follicular Lymphoma
NCT06388018

Recruiting

Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer

Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8
NCT06357676

Recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Mantle Cell Lymphoma
NCT06307548

Recruiting

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Recurrent Colorectal Carcinoma | Locally Advanced Colorectal Carcinoma | Stage III Colorectal Cancer
NCT05943496

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia
NCT05388006

Recruiting

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter Syndrome
NCT04529044

Recruiting

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma
NCT02390635

Recruiting

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARA
NCT07349771

Not yet recruiting

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Hematopoietic and Lymphatic System Neoplasm
NCT07281417

Recruiting

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Stage III Sinonasal Cancer AJCC v8 | Stage IVA Sinonasal Cancer AJCC v8 | Stage IVB Sinonasal Cancer AJCC v8 | Sinonasal Squamous Cell Carcinoma
NCT07097142

Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8 | Muscle Invasive Bladder Urothelial Carcinoma
NCT05896839

Recruiting

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Metastatic Merkel Cell Carcinoma | Metastatic Skin Squamous Cell Carcinoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Basal Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Unresectable Basal Cell Carcinoma
NCT02446600

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Undifferentiated Carcinoma
NCT07405476

Recruiting

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Colorectal Carcinoma | Colon Carcinoma | Rectal Carcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage I Rectal Cancer AJCC v8
NCT03907475

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
NCT01810913

Recruiting

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma | Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
NCT04847453

Active, not recruiting

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Recurrent AL Amyloidosis | Refractory AL Amyloidosis
NCT00352534

Completed

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor
NCT02971501

Active, not recruiting

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain
NCT01013649

Completed

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7
NCT04692103

Active, not recruiting

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Primary or Recurrent Breast Carcinoma
NCT04777045

Active, not recruiting

Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial (EDIT-CMD)

Coronary Vasospasm | Microvascular Angina | Microvascular Ischemia of Myocardium
NCT04499573

Active, not recruiting

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

B-ALL
NCT01023061

Completed

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer (RAD1)

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer
NCT05269381

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma
NCT02934529

Completed

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114)

Metastatic Colorectal Cancer
NCT02572492

Unknown

Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support (CARFI)

Multiple Myeloma
NCT05631886

Recruiting

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Lymphoma | Solid Tumor, Adult | EphA2 Overexpression | TP53 R273H | TP53 R175H | TP53 R248Q | TP53 R249S
NCT04287660

Recruiting

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Multiple Myeloma
NCT00013897

Completed

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

HIV Infections
NCT01921374

Completed

Mother-caregivers of Children With Duchenne Muscular Dystrophy (DMDK)

Other Diseases or Conditions
NCT06905522

Recruiting

A PAN-USR TB Multi-Center Trial

Pulmonary Tuberculosis
NCT03715517

Recruiting

Spinal Anesthesia For Enhanced Recovery After Liver Surgery (SAFER-L)

Pain, Postoperative | Liver Neoplasms | Hepatectomy
NCT05156437

Terminated

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) (OPTIMAL)

Endocarditis
NCT05444556

Completed

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Healthy
NCT05639712

Completed

Affective Effects of Pre-surgery Opioids: a Randomized, Doubleblind Placebo-controlled Trial (AFFECT2)

Opioid Use | Affective Symptoms
NCT06915610

Enrolling by invitation

Reengineering Cervical Cancer Screening for the 21st Century: Joint Action for a Novel Up-to-date and Sustainable Screening Program (JANUS)

Cervical Cancer Screening
NCT05831449

Completed

CPL-01 in the Management of Postoperative Pain After Bunionectomy

Bunion | Post-operative Pain
NCT01390402

Completed

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Leukemia | Chronic Myelogenous Leukemia
NCT07497750

Not yet recruiting

Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial (S@VE-LIVER)

Non Alcoholic Fatty Liver Disease

Search clinical trials for: Girls Can...Move!

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations